Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound reserpine + triamterene tablet versus valsartan + hydrochlorothiazide for primary hypertension
ChiCTR2300067920Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of reserpine, triamterene, valsartan and hydrochlorothiazide in hypertension (HTN) and essential hypertension (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Mean 24-hour systolic blood pressure reduction. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
reserpinetriamterenevalsartanhydrochlorothiazide
03
Conditions
hypertension (HTN)essential hypertension
Beyond the preview
Go deeper on ChiCTR2300067920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067920.